Meriem Bouslouk-Marx has been working for over 10 years in the field of benefit assessment, especially for orphan drugs. She advises global pharmaceutical companies on the AMNOG process in Germany.

Meriem Bouslouk-Marx joined the G-BA – Germany’s decision-making Health Technology Assessment (HTA) body for the Statutory Health Insurance (SHI) system – when the new law called AMNOG was introduced in 2011. As a game changer, AMNOG made the benefit assessment of new medicines mandatory in Germany. As part of the initial small team, she set up the procedures at the G-BA, advised applicant companies on evidence requirements and prepared binding national reimbursement decisions. Her particular focus from the outset was on new orphan drugs approved by the European Medicines Agency (EMA). She left the G-BA and set up MBM Future Health offering consultancy services to industry.

Meriem Bouslouk-Marx holds a PhD in Dental Medicine from the Friedrich Schiller University Jena and a Master of Science in International Health from the Humboldt University of Berlin/Charité.

Since 2011, she is a regular lecturer at the European Market Access University Diploma (EMAUD) in Paris.